Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$51.95
+2.9%
$52.66
$43.38
$62.88
$7.03B1.11830,213 shs1.06 million shs
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
NovoCure Limited stock logo
NVCR
NovoCure
$14.78
+4.2%
$14.21
$10.87
$83.60
$1.59B0.51.09 million shs1.15 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$208.55
+1.2%
$223.07
$180.93
$348.67
$8.08B0.57313,072 shs311,088 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$44.72
+22.3%
$32.29
$13.82
$47.00
$2.89B1.11.28 million shs5.99 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
+2.91%+2.77%-0.75%+0.23%-8.55%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
NovoCure Limited stock logo
NVCR
NovoCure
+4.16%+16.98%+2.50%+4.82%-77.59%
Penumbra, Inc. stock logo
PEN
Penumbra
+1.27%+2.07%-3.03%-17.21%-30.69%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+22.32%+26.90%+30.53%+92.59%+11.94%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.8919 of 5 stars
3.32.00.04.13.34.23.1
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
2.4338 of 5 stars
0.00.01.73.81.11.72.5
NovoCure Limited stock logo
NVCR
NovoCure
4.1516 of 5 stars
4.31.00.04.52.32.50.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.8554 of 5 stars
4.41.00.03.82.42.53.1
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
3.1761 of 5 stars
2.32.00.04.93.40.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.67
Moderate Buy$66.3327.69% Upside
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
2.56
Moderate Buy$30.88108.90% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.78
Moderate Buy$304.4545.99% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.64
Moderate Buy$43.45-2.83% Downside

Current Analyst Ratings

Latest PEN, TNDM, NVCR, HRC, and GMED Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$35.00 ➝ $50.00
5/3/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$28.00 ➝ $36.00
5/2/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$21.00
5/2/2024
NovoCure Limited stock logo
NVCR
NovoCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$24.00 ➝ $22.00
4/29/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$21.00 ➝ $45.00
4/25/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
4/25/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$34.00 ➝ $45.00
4/23/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $40.00
4/10/2024
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $28.00
4/3/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $42.00
4/3/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$290.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.02B6.89$3.71 per share13.99$29.32 per share1.77
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
NovoCure Limited stock logo
NVCR
NovoCure
$525.66M3.03N/AN/A$3.39 per share4.36
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.64$2.86 per share72.87$30.55 per share6.83
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$747.72M3.86N/AN/A$4.81 per share9.30

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$122.87M$1.1744.4015.841.497.83%8.82%7.20%5/7/2024 (Confirmed)
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.81N/AN/AN/A-36.67%-49.34%-16.75%7/25/2024 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3190.2852.402.038.59%7.49%5.60%5/7/2024 (Confirmed)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$222.61M-$2.17N/AN/AN/A-18.37%-32.33%-10.90%8/1/2024 (Estimated)

Latest PEN, TNDM, NVCR, HRC, and GMED Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.55N/A-$0.55N/AN/AN/A  
5/7/2024N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42N/A-$0.42N/AN/AN/A  
5/2/2024Q1 2024
NovoCure Limited stock logo
NVCR
NovoCure
-$0.43-$0.36+$0.07-$0.36$131.44 million$138.50 million      
2/22/2024Q4 2023
NovoCure Limited stock logo
NVCR
NovoCure
-$0.53-$0.45+$0.08-$0.45$133.80 million$133.80 million      
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      
2/21/2024Q4 2023
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.23-$0.27-$0.04-$0.08$204.86 million$196.80 million
2/20/2024Q4 2023
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.59$0.60+$0.01$1.09$608.21 million$616.53 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.10
4.88
2.72
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
NovoCure Limited stock logo
NVCR
NovoCure
1.57
5.78
5.56
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.06
3.49
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.91
3.83
3.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
24.30%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
NovoCure Limited stock logo
NVCR
NovoCure
5.67%
Penumbra, Inc. stock logo
PEN
Penumbra
5.30%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,000135.37 million102.48 millionOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,453107.61 million101.51 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.76 million36.70 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,40064.56 million63.14 millionOptionable

PEN, TNDM, NVCR, HRC, and GMED Headlines

SourceHeadline
Tandem Diabetes Care (NASDAQ:TNDM) Sets New 52-Week High Following Analyst UpgradeTandem Diabetes Care (NASDAQ:TNDM) Sets New 52-Week High Following Analyst Upgrade
americanbankingnews.com - May 4 at 1:38 AM
Why Tandem Diabetes Stock Just Jumped 22%Why Tandem Diabetes Stock Just Jumped 22%
fool.com - May 3 at 4:34 PM
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call TranscriptTandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 3 at 1:09 PM
Tandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month High After Analyst UpgradeTandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month High After Analyst Upgrade
marketbeat.com - May 3 at 12:51 PM
Tandem Diabetes Care (NASDAQ:TNDM) Earns "Overweight" Rating from Piper SandlerTandem Diabetes Care (NASDAQ:TNDM) Earns "Overweight" Rating from Piper Sandler
marketbeat.com - May 3 at 11:12 AM
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises 24 ViewTandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
zacks.com - May 3 at 10:36 AM
Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $36.00Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $36.00
marketbeat.com - May 3 at 9:33 AM
Tandem Diabetes Care Shares Rise 17% on Raised 2024 Sales OutlookTandem Diabetes Care Shares Rise 17% on Raised 2024 Sales Outlook
marketwatch.com - May 3 at 8:08 AM
Tandem Diabetes Care Inc (TNDM) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...Tandem Diabetes Care Inc (TNDM) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
finance.yahoo.com - May 3 at 8:08 AM
Q1 2024 Tandem Diabetes Care Inc Earnings CallQ1 2024 Tandem Diabetes Care Inc Earnings Call
finance.yahoo.com - May 3 at 8:08 AM
TNDM Stock Earnings: Tandem Diabetes Care Beats EPS, Beats Revenue for Q1 2024TNDM Stock Earnings: Tandem Diabetes Care Beats EPS, Beats Revenue for Q1 2024
investorplace.com - May 2 at 10:05 PM
Tandem Diabetes Care (TNDM) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesTandem Diabetes Care (TNDM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com - May 2 at 7:31 PM
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue EstimatesTandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
zacks.com - May 2 at 6:31 PM
Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial GuidanceTandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance
businesswire.com - May 2 at 4:05 PM
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY)Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY)
markets.businessinsider.com - May 2 at 8:23 AM
Tandem Diabetes Care (NASDAQ:TNDM) Stock Rating Upgraded by Wells Fargo & CompanyTandem Diabetes Care (NASDAQ:TNDM) Stock Rating Upgraded by Wells Fargo & Company
americanbankingnews.com - May 1 at 9:46 AM
How Advanced Diabetes Supply is Driving Value-Based Health OutcomesHow Advanced Diabetes Supply is Driving Value-Based Health Outcomes
hmenews.com - April 30 at 5:21 PM
Wells Fargo Upgrades Tandem Diabetes Care (TNDM)Wells Fargo Upgrades Tandem Diabetes Care (TNDM)
msn.com - April 30 at 12:21 PM
Are Investors Undervaluing Tandem Diabetes Care, Inc. (NASDAQ:TNDM) By 31%?Are Investors Undervaluing Tandem Diabetes Care, Inc. (NASDAQ:TNDM) By 31%?
finance.yahoo.com - April 29 at 4:19 PM
Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up to $35.24Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up to $35.24
marketbeat.com - April 29 at 12:12 PM
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded to Overweight at Wells Fargo & CompanyTandem Diabetes Care (NASDAQ:TNDM) Upgraded to Overweight at Wells Fargo & Company
marketbeat.com - April 29 at 8:06 AM
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at Leerink PartnrsTandem Diabetes Care (NASDAQ:TNDM) Upgraded at Leerink Partnrs
americanbankingnews.com - April 27 at 3:48 AM
Tandem Diabetes Care (NASDAQ:TNDM) Rating Increased to Outperform at SVB LeerinkTandem Diabetes Care (NASDAQ:TNDM) Rating Increased to Outperform at SVB Leerink
americanbankingnews.com - April 27 at 1:54 AM
Leerink Partners Upgrades Tandem Diabetes Care (TNDM)Leerink Partners Upgrades Tandem Diabetes Care (TNDM)
msn.com - April 26 at 1:44 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Globus Medical logo

Globus Medical

NYSE:GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Hill-Rom logo

Hill-Rom

NYSE:HRC
Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.
NovoCure logo

NovoCure

NASDAQ:NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Tandem Diabetes Care logo

Tandem Diabetes Care

NASDAQ:TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.